Family History
411 articles
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.
The ABCs of Genetic Testing
There are a number of different genetic mutations that can cause familial pancreatic cancer. This article explains some of the most common ones.
Sometimes Things Get Worse Before They Get Better
Matthew Rosenblum thought his time was limited after a pancreatic cancer diagnosis at age 32, but he’s a BRCA2 carrier, which opened treatment options.
Strong Like a Dinosaur
Diagnosed with pancreatic cancer on her 40th birthday, Andrea Barkstrom receives chemotherapy and is living up to her motto: Strong Like a Dinosaur.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
Damage as a Way to Repair Pancreatic Cancer
Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.
Lucky to Find It Early
When Jeneen Genna did not feel well her doctor searched until they found pancreatic cancer. The BRCA2 mutation has her in a clinical trial.
Pancreatic Cancer Tissue Helps Unlock the Disease’s Secrets
Dr. Christine Iacobuzio-Donahue at Memorial Sloan Kettering is using techniques from evolutionary biology to learn how pancreatic cancer grows.
Personalized Treatment Plans in the Fight Against PC
David Dessert explains that his aunt’s genetic testing for BRCA2 mutation directed his own treatment for pancreatic cancer.
Genetic Testing Leads Me to a PARP Inhibitor Trial
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial.
Facing Pancreatic Cancer and Making the Most of Borrowed Time
With a young family, Justin Baker is hoping for more time because he has a genetic mutation that favors certain treatments.
Tumor RNA Testing Leads to Treatment with a New Drug
When treatment stopped working for Adam Deal, genetic testing of his tumor RNA found a mutation that made him eligible to try a new drug.
The Butterfly Effect and Living Every Day to My Fullest
Because Helene Avraham-Katz has the BRCA2 mutation, certain chemotherapies work better and she is eligible for specific clinical trials.